AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$AMPH

Zhou Rong sold $239K of AMPH

Zhou Rong (SENIOR EVP, PRODUCTION CENTER) sold 10,000 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $23.94 ($0.24M total) on 2026-09-16.

Original reporting
SEC EDGAR · Zhou Rong
Published Sep 17, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AMPH
Neutral
medium confidence
Mentioned
$AMPH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMPHNeutralLow
01

Why it matters

The sale represents a modest reduction in insider ownership, unlikely to move the stock.

02

Market read

Minor insider sell; limited trading relevance.

03

What to watch

Potential upcoming regulatory or product milestones not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑16

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$AMPHNeutralMedium confidence
Context

Senior EVP Zhou Rong sold 10,000 shares of Amphastar for $239,404 on 2026-09-16.

Expected impact

Limited short-term pressure; price likely unchanged.

Evidence & confidence

The transaction size is small relative to market cap and holdings, so market reaction is expected to be minimal.

Market effects

Sector

No broader sector impact; insider activity is company‑specific.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Officer
    Zhou Rong

    Senior EVP, Production Center at Amphastar Pharmaceuticals

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMPH insider trading history →

Related articles

AUG 21
$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

finance.yahoo.com3 min
AUG 14
$AMPHMedAI 8/10

Amphastar (AMPH) Q2 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.

fool.com6 min
AUG 6
$AMPHMedAI 8/10

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.

financialcontent.com4 min
AUG 6
$AMPHMed

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per share, for the second quarter ​ - Adjusted no

SEC EDGAR 8-K7 min
JUL 9
$AMPHMedAI 8/10

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.

medicaldaily.com5 min
JUN 10
$AMPHMed

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash

finance.yahoo.com7 min